Home > Insider Trading > Filing (0000899243-23-014464)

Filing Details

Accession Number:: 0000899243-23-014464
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-06-05 16:46:00
Reporting Period:: 2023-06-05

Accepted Time:: 2023-06-05 16:46:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1062822	Lexicon Pharmaceuticals Inc.	LXRX	()	N4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053906	S.a. Group Artal	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No
1218180	S.c.a. International Artal	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No
1283968	S.a. Westend	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No
1340096	Invus Public Equities Advisors, Llc	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1340097	Invus Public Equities, L.p.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1404553	Invus Advisors, L.l.c.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1404570	Invus, L.p.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1460840	Westend Administratiekantoor Stichting	Claude Debussylaan 46 Amsterdam P7 1082 MD	Yes	No	Yes	No
1522131	S.a. Management International Artal	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No
1841311	Amaury Wittouck	Valley Park, 44, Rue De La Vallee Luxembourg N4 L-2661	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-06-05	27,775,050	$2.60	78,634,381	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,516,214	Indirect	See Footnotes
Common Stock	35,402,689	Indirect	See Footnotes

Footnotes

On May 31, 2023, Artal International S.C.A. entered into a purchase agreement (the "Purchase Agreement") with the Issuer pursuant to which Artal International S.C.A. agreed to purchase 24,152,218 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), of the Issuer at a price of $2.60 per share (the "Purchase Price"). The Purchase Agreement also provided Artal International S.C.A. the right to purchase from the Issuer, on a pro rata basis, up to an additional 3,622,832 shares of Issuer Common Stock at a price per share equal to the Purchase Price. On June 1, 2023, pursuant to the 2023 Purchase Agreement, Artal International S.C.A. exercised its right to purchase an additional 3,622,832 shares of Issuer Common Stock at a price per share equal to the Purchase Price. The purchase closed on June 5, 2023.
These securities are directly held by Artal International S.C.A.
These securities are directly held by Invus Public Equities, L.P.
These securities are directly held by Invus, L.P.
Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.